Roman Fischer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1402436/publications.pdf

Version: 2024-02-01

32 papers	1,944 citations	331538 21 h-index	477173 29 g-index
32 all docs	32 docs citations	32 times ranked	3072 citing authors

#	Article	IF	Citations
1	Interrelation of Oxidative Stress and Inflammation in Neurodegenerative Disease: Role of TNF. Oxidative Medicine and Cellular Longevity, 2015, 2015, 1-18.	1.9	486
2	Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12304-12309.	3.3	129
3	Selective Targeting of TNF Receptors as a Novel Therapeutic Approach. Frontiers in Cell and Developmental Biology, 2020, 8, 401.	1.8	126
4	Role of Caspases in Cytokine-Induced Barrier Breakdown in Human Brain Endothelial Cells. Journal of Immunology, 2012, 189, 3130-3139.	0.4	112
5	A TNF Receptor 2 Selective Agonist Rescues Human Neurons from Oxidative Stress-Induced Cell Death. PLoS ONE, 2011, 6, e27621.	1.1	103
6	Astrocyteâ€specific activation of TNFR2 promotes oligodendrocyte maturation by secretion of leukemia inhibitory factor. Glia, 2014, 62, 272-283.	2.5	91
7	TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death and Disease, 2020, 11, 212.	2.7	90
8	Inflammation and Oxidative Stress in Multiple Sclerosis: Consequences for Therapy Development. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-19.	1.9	73
9	Development of a Mouse Pain Scale Using Sub-second Behavioral Mapping and Statistical Modeling. Cell Reports, 2019, 28, 1623-1634.e4.	2.9	65
10	Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy. Antibodies, 2015, 4, 48-70.	1.2	63
11	Antibody-Mediated Inhibition of TNFR1 Attenuates Disease in a Mouse Model of Multiple Sclerosis. PLoS ONE, 2014, 9, e90117.	1.1	55
12	TNF receptor 2 protects oligodendrocyte progenitor cells against oxidative stress. Biochemical and Biophysical Research Communications, 2013, 440, 336-341.	1.0	49
13	TNFR2 promotes Treg-mediated recovery from neuropathic pain across sexes. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17045-17050.	3.3	45
14	Soluble TNFÎ± Signaling within the Spinal Cord Contributes to the Development of Autonomic Dysreflexia and Ensuing Vascular and Immune Dysfunction after Spinal Cord Injury. Journal of Neuroscience, 2018, 38, 4146-4162.	1.7	42
15	Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Scientific Reports, 2018, 8, 13628.	1.6	41
16	Ligand-induced internalization of TNF receptor 2 mediated by a di-leucin motif is dispensable for activation of the NFÎºB pathway. Cellular Signalling, 2011, 23, 161-170.	1.7	37
17	Tumor necrosis factor receptor 1 inhibition is therapeutic for neuropathic pain in males but not in females. Pain, 2019, 160, 922-931.	2.0	37
18	Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2. Scientific Reports, 2017, 7, 6607.	1.6	34

#	Article	IF	Citations
19	Selective Activation of Tumor Necrosis Factor Receptor <scp>II</scp> Induces Antiinflammatory Responses and Alleviates Experimental Arthritis. Arthritis and Rheumatology, 2018, 70, 722-735.	2.9	34
20	The E3 ubiquitin ligases HOIP and cIAP1 are recruited to the TNFR2 signaling complex and mediate TNFR2-induced canonical NF-Î²B signaling. Biochemical Pharmacology, 2018, 153, 292-298.	2.0	27
21	Exogenous activation of tumor necrosis factor receptor 2 promotes recovery from sensory and motor disease in a model of multiple sclerosis. Brain, Behavior, and Immunity, 2019, 81, 247-259.	2.0	26
22	Role of Peripheral Immune Cells for Development and Recovery of Chronic Pain. Frontiers in Immunology, 2021, 12, 641588.	2.2	26
23	Fundamentally different roles of neuronal TNF receptors in CNS pathology: TNFR1 and IKKÎ² promote microglial responses and tissue injury in demyelination while TNFR2 protects against excitotoxicity in mice. Journal of Neuroinflammation, 2021, 18, 222.	3.1	25
24	Neuropathic Pain in Multiple Sclerosisâ€“Current Therapeutic Intervention and Future Treatment Perspectives. , 0, , 53-69.		25
25	Attenuating Neurogenic Sympathetic Hyperreflexia Robustly Improves Antibacterial Immunity After Chronic Spinal Cord Injury. Journal of Neuroscience, 2020, 40, 478-492.	1.7	24
26	The TNFR1 Antagonist Atrosimab Is Therapeutic in Mouse Models of Acute and Chronic Inflammation. Frontiers in Immunology, 2021, 12, 705485.	2.2	19
27	Characterization of mouse cell line IMA 2.1 as a potential model system to study astrocyte functions. ALTEX: Alternatives To Animal Experimentation, 2012, 29, 261-274.	0.9	18
28	Continuous infusion of an agonist of the tumor necrosis factor receptor 2 in the spinal cord improves recovery after traumatic contusive injury. CNS Neuroscience and Therapeutics, 2019, 25, 884-893.	1.9	14
29	Superior Treg-Expanding Properties of a Novel Dual-Acting Cytokine Fusion Protein. Frontiers in Pharmacology, 2019, 10, 1490.	1.6	14
30	Synaptic alterations and immune response are sexually dimorphic in a non-pertussis toxin model of experimental autoimmune encephalomyelitis. Experimental Neurology, 2020, 323, 113061.	2.0	14
31	Genetic engineering of a TNFR2 agonist to promote immunomodulation and neuroprotection. Journal of Neuroimmunology, 2014, 275, 218.	1.1	0
32	Anti-TNFR1 targeting in humanized mice ameliorates disease in a model of multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 178-179.	1.1	0